Healing, Feeding, & Providing for People – at Scale.

General Partner, NFX Bio

Omri Amirav Drory, Ph.D.

Omri Amirav-Drory, Ph.D. is a General Partner and head of NFX Bio. He is a scientist and an operator who has founded, scaled, and invested in some of today’s most important new tech bio companies. He founded Genome Compiler, which developed software for genetic engineers and molecular and synthetic biologists, and led it to a successful acquisition by Twist Bioscience. He went on to lead Corporate Development at Twist, a next-generation DNA synthesis company currently valued at approximately $10 Billion. Omri was also the founding partner at Tech.Bio where he invested and advised in companies like Mammoth Biosciences, immunai, C2i Genomics, and more. He is a graduate of Tel Aviv University where he received a B.S. in Biochemistry and Molecular Biology and a Ph.D. in Biochemistry. He was a Fulbright Postdoctorate in Biochemistry & Molecular Biology at Stanford University school of medicine & HHMI. One of the most connected leaders in the tech biofield, Omri understands what it means to be a Scientist-CEO and is committed to a future where this is the norm, not the exception. If you want to reach Omri for investment, you can email him at [email protected], and it’s best to send him a private link to your Company Brief.

Read More

CEO, Twist Bioscience (Investment Committee)

Emily Leproust, Ph.D.

As an early pioneer in the high-throughput synthesis and sequencing of DNA, Dr. LeProust is disrupting the process of gene synthesis to enable the exponential growth of synthetic biology applications in multiple fields including medicine, DNA data storage, agricultural biology, and industrial chemicals. In 2015, she was named one of Foreign Policy’s 100 Leading Global Thinkers for fast-tracking the building blocks of life, and Fast Company named her one of the most creative people in business for synthesizing DNA faster than ever. Prior to Twist Bioscience, she held escalating positions at Agilent Technologies where she architected the successful SureSelect product line that lowered the cost of sequencing and elucidated mechanisms responsible for dozens of Mendelian diseases. She also developed the Oligo Library Synthesis technology, where she initiated and led product and business development activities for the team. Dr. LeProust designed and developed multiple commercial synthesis platforms to streamline microarray manufacturing and fabrication. Prior to Agilent, she worked with Dr. X. Gao at the University of Houston developing DNA and RNA parallel synthesis processes on solid support, a project developed commercially by Xeotron Corporation. Dr. LeProust has published over 30 peer-reviewed papers—many on applications of synthetic DNA and is the author of numerous patents. She earned her Ph.D. in organic chemistry from the University of Houston and her M.Sc. in industrial chemistry from the Lyon School of Industrial Chemistry in France.

Read more

General Partner, NFX (Investment Committee)

James Currier

James is one of Silicon Valley’s top early-stage VC’s and a leading expert in growth and network effects. He is an investor in Mammoth Biosciences (founded by Trevor Martin, Janice Chen, Lucas Harrington, and Nobel Prize-winner Jennifer Doudna, the inventor of CRISPR technology), Twist Bioscience, Genome Compiler (acquired by Twist), C2i Genomics, and more.He’s a four-time serial entrepreneur who pioneered user-generated models, viral marketing, a/b testing, crowdsourcing, and myriad other growth techniques now followed by nearly all technology companies. He sees biotech as the next frontier of technology and believes a platform approach is critical to building tech bio companies that can rapidly scale to meet the changing demands of society. James holds an M.B.A. from Harvard Business School, a B.A. in Political Economics from Princeton, and is a Henry Crown Fellow at the Aspen Institute.

Read more

General Partner, NFX (Investment Committee)

Gigi Levy-Weiss

One of the most prolific technology investors in Israel, Gigi is a two-time CEO, founder, board member, and was previously a super-angel. He served as the CEO of 888 Holdings (LSE: 888.L), one of the world’s leading online gaming entertainment companies in the world. Prior to 888, Gigi was Division President of Amdocs, a world leading billing and CRM provider (NYSE: DOX). Earlier he held various roles in Israel tech companies and founded several startups including Playtika (acquired for $4.4 billion by China Consortium / Cesars), Beach Bum, InceptionVR, and others. An investor in numerous leading tech bio companies, Gigi has backed Mammoth Biosciences (founded by Trevor Martinand Nobel Prize-winning chemist Jennifer Doudna – the Founder of CRISPR technology), Twist Bioscience, Genome Compiler (acquired by Twist), C2i Genomics, and more. Gigi has an M.B.A. from Kellogg Graduate School of Management and was a Pilot in the Israeli Air Force.

Read more

Principal

Gita Reinitz

Gita Reinitz is a Principal at NFX Bio. She previously was a Principal at Tech.Bio where she worked closely with companies like Wild Bio, C2i Genomics, Armada biosystems, and more. Before that, she was in Business Development at LifeGene and was the Life Science Sector Head at Gvahim. She has also been a Research Scientist in the Nanotechnology Center at Bar Ilan University. She holds a B.S. in Biotechnology from Bar Ilan University. Gita is passionate about funding companies at the intersection of tech and bio, and leveraging her strong network to give NFX Bio CEO’s an edge.

Read more

NFX Bio Content

To see the full library of Bio-related content, click here.

Subscribe to nfx CONTENT

Insider Founder resources delivered weekly to your inbox